American Society of Hirudotherapy

Efficacy and safety of bivalirudin for percutaneous coronary intervention in acute coronary syndromes: a meta-analysis of randomized-controlled trials

Review published in Clinical research in cardiology : official journal of the German Cardiac Society (2018)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Meta-analysisClinical LiteratureDrug DevelopmentSafety & Infection ControlSalivary PharmacologyNührenberg TG et al. · Clinical research in cardiology : official journal of the German Cardiac Society, 2018

Abstract

AIMS: The efficacy and safety of bivalirudin in patients undergoing percutaneous coronary intervention (PCI) for treatment of acute coronary syndromes (ACS) remains controversial despite recent evidence from large randomized-controlled trials (RCTs). Thus, this systematic review and meta-analysis sought to investigate the efficacy and safety of bivalirudin as compared to heparin in patients with ACS undergoing PCI. METHODS AND RESULTS: Medline/PubMed, Cochrane Central Register of Controlled Trials, and Clinical Trials.gov databases were searched for RCTs. Primary endpoint was MACE consisting of all-cause death, myocardial infarction, and stroke within 30 days. Secondary endpoints were components of the primary endpoint and stent thrombosis. The primary safety endpoint was major bleeding. We identified 12 RCTs comprising 33,844 patients. Between bivalirudin and heparin, there were no significant differences for MACE (OR 1.06; 95% CI 0.96-1.17; p = 0.24), death, myocardial infarction, and stent thrombosis. Similar results were seen following stratification by use of glycoprotein inhibitors (GPI). Major bleeding trended to be less frequent in patients treated with bivalirudin. However, no safety benefit for bivalirudin was seen when use of GPI was balanced between groups (OR 0.88; 95% CI 0.67-1.16; p = 0.35; p for heterogeneity < 0.01). CONCLUSIONS: Compared with heparin, bivalirudin was associated with a similar incidence of ischemic events following PCI for ACS. An association of bivalirudin with decreased bleeding was not seen with balanced use of GPI.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleMeta-AnalysisSystematic Review
Indexed MeSH termsAcute Coronary SyndromeAntithrombinsGlobal HealthHirudinsHumansIncidencePeptide FragmentsPercutaneous Coronary InterventionRecombinant ProteinsThrombosisTreatment Outcome

Summary

In a meta-analysis of 12 randomized trials (33,844 patients with acute coronary syndromes undergoing PCI), bivalirudin and heparin gave similar 30-day MACE, ischemic outcomes and stent thrombosis; any bleeding advantage disappeared when glycoprotein inhibitor use was balanced.

Why This Matters for Hirudotherapy

This systematic review and meta-analysis of 12 randomized-controlled trials (33,844 patients) compared bivalirudin to heparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention, finding no significant difference in major adverse cardiovascular events (OR 1.06; 95% CI 0.96-1.17) and suggesting that bivalirudin's apparent bleeding advantage was not observed when glycoprotein inhibitor use was balanced between groups. Bivalirudin is a synthetic direct thrombin inhibitor structurally modeled on hirudin, the anticoagulant from medicinal leech saliva, so this study is relevant to understanding how a leech-secretome-inspired anticoagulant performs in contemporary interventional cardiology. However, this is an evaluation of a specific pharmaceutical product in PCI rather than a study of leech therapy itself, and its findings cannot be directly extrapolated to hirudotherapy or the broader leech secretome.

Citation

Reference (Vancouver style)

Nührenberg TG, Hochholzer W, Mashayekhi K, Ferenc M, Neumann FJ. Efficacy and safety of bivalirudin for percutaneous coronary intervention in acute coronary syndromes: a meta-analysis of randomized-controlled trials. Clin Res Cardiol. 2018;107(9):807-815. doi:10.1007/s00392-018-1251-1. PMID: 29654437

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.